口服重组甲硫氨酸酶可使骨转移前列腺癌患者 PSA 降低 70%，晚期卵巢癌患者血循环中甲硫氨酸降低 50%。
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient.
机构信息
AntiCancer, Inc., San Diego, CA, U.S.A.
出版信息
Anticancer Res. 2020 May;40(5):2813-2819. doi: 10.21873/anticanres.14254.
BACKGROUND/AIM: Methionine addiction is a general and fundamental hallmark of cancer. Methionine addiction can be targeted by methionine restriction (MR). Our laboratory has studied methionine addiction in cancer and MR for almost 50 years. The present study describes oral recombinant methioninase (o-rMETase), as a supplement, to induce MR in cancer patients.
PATIENTS AND METHODS
One patient, a 67-year-old female with high-stage ovarian cancer took o-rMETase twice a day at 250 units per dose for approximately one month. A second patient, a 76-year-old male with bone-metastatic prostate cancer, took o-rMETase twice a day at 250 units per dose during three months.
RESULTS
The first patient's circulating methionine levels decreased 50% within 4 hours of taking 250 units of o-rMETase. The second patient's PSA dropped approximately 70% over 3 months. During this time the patient's hemoglobin increased.
CONCLUSION
o-rMETase has no side effects and is potentially efficacious. Future studies involving larger cohorts of patients with high-stage cancer are required to determine if o-rMETase, as a supplement, can increase survival and improve the quality of life.
背景/目的：甲硫氨酸成瘾是癌症的普遍和基本特征。甲硫氨酸成瘾可以通过甲硫氨酸限制（MR）来靶向治疗。我们的实验室近 50 年来一直在研究癌症中甲硫氨酸成瘾和 MR。本研究描述了口服重组甲硫氨酸酶（o-rMETase）作为补充剂，以诱导癌症患者的 MR。
患者和方法
一名 67 岁的女性晚期卵巢癌患者每天服用 o-rMETase 两次，每次 250 单位，大约一个月。另一名 76 岁的男性患有骨转移前列腺癌，每天服用 o-rMETase 两次，每次 250 单位，持续三个月。
结果
服用 250 单位 o-rMETase 后 4 小时内，第一例患者的循环甲硫氨酸水平降低了 50%。第二个患者的 PSA 在 3 个月内下降了约 70%。在此期间，患者的血红蛋白增加。
结论
o-rMETase 没有副作用，并且具有潜在的疗效。需要进行涉及更多晚期癌症患者的研究，以确定 o-rMETase 是否可以作为补充剂来提高生存率和改善生活质量。
Zotero 插件